Edit Entry

Leslie R. Demars, M.D.

Title(s):
Acting Chair and Associate Professor of Obstetrics and Gynecology

Department(s):
Obstetrics and Gynecology

Education:
MD 1987
Tufts University, BS 1983

Contact Information:

Dartmouth-Hitchcock Medical Center
1 Medical Center Drive
Lebanon NH 03756

Phone: (603)-653-3530
Fax: 603-653-3545
Email: Leslie.R.DeMars@hitchcock.org


Professional Interests:

Chemotherapy of gynecologic malignancies
Reproductive and gynecologic function after cancer therapy
Familial cancer

Grant Information:

7/15/99 - Principal Investigator, Evaluation of 3-Day Topotecan in Recurrent
10/30/00 Ovarian and Primary Peritoneal Cancer, Investigator initiated study, Sponsor: Glaxo-Smith Kline

09/01/2002 - Local Principal Investigator, Actimmune (Interferon gamma-1b) in Combination 08/31/2007 with Chemotherapy (Carboplatin/Paclitaxel) for First-Line Therapy of Advance
Ovarian or Primary Peritoneal Carcinoma. Sponsor: InterMune Incorporated
($8,877)

11/05/2002 - Local Principal Investigator, A Randomized Phase III Trial of Gemzar vs Doxil
11/04/2004 with Crossover Treatment Option for Patients with Platinum Refractory Ovarian,
Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third Line
Chemotherapy. Sponsor: Lilly Pharmaceuticals ($16,000)

02/07/2003 - Local Principal Investigator, Study of Progression-Free Survival in ChemoFx 02/28/2004 Assay Sensitive or Resistant Subjects with Stage III-IV Primary or Recurrent
Epithelial Ovarian Cancer or Primary Peritoneal Carcinoma. Sponsored by
Precision Therapeutics, Inc. ($11,400)

1/10/1997 - Co-Investigator, Open Label, Randomized, Comparative, Multi-center, Phase III 8/15/1997 Study of Oral vs Intravenous Topotecan as a Single Agent, Second-Line Therapy
Administered for Five Days in Patients with Advanced Ovarian Cancer
PI - Jackson B. Beecham, Sponsor: Smith Kline Beecham ($41,909)

1/15/1998 - Local Principal Investigator, A Phase III Study of PSC 833 in Combination with
10/22/1999 Paclitaxel and Carboplatin vs Paclitaxel and Carboplatin Alone in Patients with
Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or
Primary Cancer of the Peritoneum, Sponsor: Novartis Pharmaceuticals
Corporation ($49,387)

10/14/2005- Local Principal Investigator, Telcyta and carboplatin versus lipsomal encapsulated
10/13/2007 Doxorubicin in the treatment of platinum resistant ovarian cancer. Sponsored by
Telik Pharmaceuticals $46,725 proposed, $4,900 received

GOG 182: Principal Investigator, A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combination in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma Sponsor: National Cancer Institute

GOG 198: Principal Investigator, Randomized Study of Tamoxifen Vs Thalidomide (NSC#66847) in Patients with Biochemical Recurrence Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy, Sponsor: National Cancer Institute

2006- Principal Investigator, Intraoperative Lymphatic Mapping and Sentinel Node (SN) Identification in Patients with Squamous Cell Carcinoma of the Vulva, Sponsor: National Cancer Institute

2005- Principal Investigator, Randomized Study of Tamoxifen Vs Thalidomide (NSC#66847) in Patients with Biochemical Recurrence Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy, Sponsor: National Cancer Institute

2006- Principal Investigator, Prospective Study of Risk Reducing Salpingo- Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer, Sponsor: National Cancer Institute

2005- Principal Investigator, A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix, Sponsor: National Cancer Institute


7/31/2006 - Local Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled,
7/30/2009 Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of
Procrit (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients
Receiving Chemotherapy for Advanced Ovarian Cancer. Sponsored by Ortho
Biotech, Inc. ($38,552)

10/2/2006 - Local Principal Investigator, An Open-Label Single-Arm, Phase II Safety and
10/1/2008 Tolerability Study of Catumaxomab (Anti-EpCam x Anti-CD3) In Women with
Advanced Epithelial Ovarian Cancer After a Complete Response to
Chemotherapy, Sponsor: Fresinius Biotech North America Incorporated
($60,000)

8/15/2006 - Local Principal Investigator, A Randomized, Parallel Group, Open-Label Active
8/14/2008 Controlled, Multicenter Phase III Trial of Patupilone (EPO9906) vs Pegylated
Liposomal Doxorubicin (Doxil/Caelyx) in Taxane/Platinum Refractory/
Resistant Patients with Recurrent Epithelial Ovarian, Primary Fallopian or
Primary Peritoneal Cancer. Sponsor: Novartis Pharmaceuticals Corporation
($297,568)

8/22/2006 - Local Principal Investigator, Phase I/II Study of ZK-Epothilone (ZK-Epo;
8/21/2008 ZK219477)in Combination with Carboplatin in Patients with Platinum-Sensitive,
Recurrent Ovarian Cancer. Sponsor: Berlex Laboratories ($262,500)

6/06/2006 - Local Principal Investigator, A Single-Arm, Open-Label, Phase II Study to Assess
6/05/2008 the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-
EpCAM xAnti- CD3) Administered Intraperitoneally in Ovarian Cancer Patients
With Recurrent Symptomatic Malignant Ascites. Sponsor: Parexel
International Corporation ($83,451)

2006- Principal Investigator, Phase III Randomized Study of Cisplatin and Paclitaxel (24 Hour Infusion) v Carboplatin and Paclitaxel (3 Hour Infusion) in Optimal Stage III Epithelial Ovarian Carcinoma, Sponsor: National Cancer Institute

2006- Principal Investigator, A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma, Sponsor: National Cancer Institute

2006 - Principal Investigator, Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol and Acetate) in Patients With Stage III and IV or Recurrent Endometrial Cancer, Sponsor: National Cancer Institute

7/17/2000 – Local Principal Investigator, Gynecologic Oncology Group Trials, affiliate
3/31/2008 member ofUniversity of North Carolina. ($105,375)

1995-1997 Principal Investigator, Gynecologic Oncology Group; Eastern Virginia Medical School, Norfolk Virginia

Pending

3/01/2007- Co-Investigator, Immunotherapy of Ovarian Cancer Using Chimeric NK-
2/28/2010 Receptors. Principal Investigator Charles Sentman, Ph.D. Sponsor: Department of
Defense, U.S. Army Medical Research and Material Command
($787,208 proposed)

2006 A Molecular Staging Study of Endometrial Carcinoma, National Cancer Institute


Other Extramural Funding:

2005 VFW Women's Auxiliary Grant, unrestricted grant to the Urogynecology Division, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center

Other Research Projects:

2000-2002 Faculty Advisor, Use of neuraxial analgesia in gynecologic oncology patients. Resident research project by Michelle Mitchell, M.D.

2004-present Faculty Advisor, The risk of intra-peritoneal tumor seeding of endometrial cancer with different hysteroscopic media. Resident research project by Rachel Ware, M.D.

2005 Faculty Advisor, The carcinoma to sarcoma ratio in uterine carcinosarcoma, and its prognostic significance, retrospective study. Student research project by Emily J. Walker, DMS IV. (no funding)

Co-investigator, Induction of immune response by chimeric T cell ligand in ovarian cancer cells. PI Charles Sentman, PhD, Department of Microbiology

Courses Taught:

Medical Student and Resident Education

1991 - 1992 Conduct weekly colposcopy clinics for residents in Obstetrics and Gynecology, colposcopy, treatment and follow-up of patients with abnormal Pap smears. Conduct gynecology clinic, staff resident gynecologic surgical procedures.

1992 -1 994 Responsible for daily clinical teaching of residents and medical students in clinics and operating room. Present semi-annual didactic lectures of selected oncology topics as part of rotating departmental curriculum. Participate in weekly tumor board discussion.

1994 - 1996 Supervise daily clinical care of patients on Gyn oncology Service, responsible
for daily teaching rounds of residents and medical students. Conduct weekly
Gyn oncology tumor board, participated in monthly multi-disciplinary tumor board. Present biweekly didactic lecture to medical students on gynecologic oncology topics.

1997 - present Supervise daily clinical care of patients on Gyn oncology Service, responsible
for daily teaching rounds of residents and medical students. Participate in
weekly multi-disciplinary Gyn oncology tumor board. Present selected topics
in Gyn oncology as part of rotating resident didactic curriculum.


Selected Publications:

 

  • Gallion H, Christopherson WA, Coleman RL, DeMars LR, Herzog T, Hosford, S, Schellhas, H, Wells, A & Sevin, B. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. International Journal of Gynecology Cancer. 2006

  • Mengshol SC, DeMars LR, Schned AR. Gliomatosis peritonei and teratomatous implant with carcinomatous transformation presenting 54 years following oophorectomy for dermoid cyst. [Case Report] Gynecology Oncology. 2004

  • DeMars LR. The impact of cancer therapy on reproductive function. Obstetricsc and Gynecology Survey. 2001

  • White HD, Musey LK, Andrews MM, Yeaman GR, DeMars LR, Manganiello PD, Howell AL, Wira CR, Green WR, McElrath MJ. Human immunodeficiency virus-specific and CD3-redirected cytotoxic T lymphocyte activity in the human female reproductive tract: lack of correlation between mucosa and peripheral blood. Journal of Infectious Diseases. 2001

  • Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996